This grant is for the purpose of funding research into the complex mechanisms by which incretin mimetics, including GLP-1, GIP-1, and dual agents, influence cancer risk. The National Institutes of Health (NIH) is offering this grant to promote both preclinical and patient-based studies that delve into how these widely used agents impact the development of various cancers. The program aims to attract talented scientists to explore the long-term effects on cancer risk, moving beyond shorter-term outcomes such as weight loss or diabetes management. Existing data suggests these agents may have a dual effect, potentially increasing the risk for some obesity-related cancers while decreasing it for others. This funding initiative will advance our understanding of these critical biological interactions.
Opportunity ID: 357202
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | PAR-25-069 |
Funding Opportunity Title: | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Nov 18, 2024 |
Last Updated Date: | Nov 18, 2024 |
Original Closing Date for Applications: | Jan 07, 2027 |
Current Closing Date for Applications: | Jan 07, 2027 |
Archive Date: | Feb 12, 2027 |
Estimated Total Program Funding: | – |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Native American tribal governments (Federally recognized) For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Private institutions of higher education Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Independent school districts Special district governments State governments City or township governments |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers. |
Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-069.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Folder 357202 Full Announcement-PAR-25-069 -> PAR-25-069-Full-Announcement.pdf
Packages
Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288791 | Jan 05, 2025 | Jan 07, 2027 | View |
Package 1
Mandatory forms
357202 RR_SF424_5_0-5.0.pdf
357202 PHS398_CoverPageSupplement_5_0-5.0.pdf
357202 RR_OtherProjectInfo_1_4-1.4.pdf
357202 PerformanceSite_4_0-4.0.pdf
357202 RR_KeyPersonExpanded_4_0-4.0.pdf
357202 PHS398_ResearchPlan_5_0-5.0.pdf
357202 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357202 RR_Budget_3_0-3.0.pdf
357202 RR_SubawardBudget30_3_0-3.0.pdf
357202 PHS398_ModularBudget_1_2-1.2.pdf
357202 PHS_AssignmentRequestForm_4_0-4.0.pdf